Skip to content

ZIVO BIOSCIENCE, INC.: 10-K filed 2015-04-06

What ZIVO BIOSCIENCE, INC. reported in its annual report filed 2015-04-06 (fiscal FY 2014): 25 published measures, 51 facts as tagged in accession 0001078782-15-000536.

This filing

Form
10-K (annual report)
Filed
2015-04-06
Fiscal period
fiscal FY 2014
Accession
0001078782-15-000536 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ZIVO BIOSCIENCE, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-12-31101,857USD
At 2013-12-312,174,403USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-12-316,471,025USD
At 2013-12-3111,768,263USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-12-31-6,369,168USD
At 2013-12-31-9,593,860USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-12-311,383USD
At 2013-12-31493,104USD
At 2013-01-0147,147USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-12-31680,811USD365
2013-01-02 to 2013-12-31-10,095,878USD364

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2014-01-01 to 2014-12-31-2,736,046USD365
2013-01-02 to 2013-12-31-2,986,213USD364

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2014-01-01 to 2014-12-310USD365
2013-01-02 to 2013-12-310USD364

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2014-01-01 to 2014-12-312,244,325USD365
2013-01-02 to 2013-12-313,763,547USD364

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2014-01-01 to 2014-12-310USD365
2013-01-02 to 2013-12-31-331,377USD364

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-12-31-41,925,281USD
At 2013-12-31-42,606,092USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2014-01-01 to 2014-12-31125,327,071shares365
2013-01-02 to 2013-12-31112,214,131shares364

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-12-3168,750USD
At 2013-12-311,392,126USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-12-31-5,153,137USD365
2013-01-02 to 2013-12-31-3,110,197USD364

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-12-3133,107USD
At 2013-12-31688,527USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2014-01-01 to 2014-12-31-589,573USD365
2013-01-02 to 2013-12-31-441,477USD364

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-12-316,233,983USD
At 2013-12-3110,877,452USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2014-12-311,225,589USD
At 2013-12-31483,208USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-01-01 to 2014-12-311,971,175USD365
2013-01-02 to 2013-12-311,018,023USD364

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-12-31128,773,859shares
At 2013-12-31116,852,093shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-12-3135,427,339USD
At 2013-12-3132,895,380USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2014-12-311,238,994USD
At 2013-12-31738,686USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2014-01-01 to 2014-12-31680,811USD365
2013-01-02 to 2013-12-31-10,095,878USD364

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-12-31907,156USD365
2013-01-02 to 2013-12-311,189,812USD364

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2014-01-01 to 2014-12-310USD365
2013-01-02 to 2013-12-310USD364

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-12-31744,273USD365
2013-01-02 to 2013-12-31-455,432USD364

Inspect the source

Entity
ZIVO BIOSCIENCE, INC. / CIK 0001101026
Captured
2026-09-20T05:23:02.675Z
SEC response SHA-256
a67c6f73387834b08f1985c02ad3ba915b8082582e19652219d78b25a60d946c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001101026.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))